Diagnosis And Treatment Of Ocular Inflammatory Disease (uveitis)

$286,009ZIAFY2016EYNIH

National Eye Institute

Investigators

Linked publications, trials & patents

Paper 27482471 Paper 27124793 Paper 26829594 Paper 26035763 Paper 26035762 Paper 25911752 Paper 25515573 Paper 25064724 Paper 25017415 Paper 24885153 Paper 24835759 Paper 24342020 Paper 24332536 Paper 24321475 Paper 24315290 Paper 24171649 Paper 23957503 Paper 23818712 Paper 23795984 Paper 23689994 Paper 23521173 Paper 23514269 Paper 23514122 Paper 23497844 Paper 23392263 Paper 23252656 Paper 23062650 Paper 21816251 Paper 21751146 Paper 21680024 Paper 21567211 Paper 21498606 Paper 21210752 Paper 21093921 Paper 20662664 Paper 20642344 Paper 20606023 Paper 20601663 Paper 20508050 Paper 20482392 Paper 20337261 Paper 20234333 Paper 20141355 Paper 20065216 Paper 20042178 Paper 20031223 Paper 20006905 Paper 19996825 Paper 19969366 Paper 19878127 Paper 19651312 Paper 19570522 Paper 19506593 Paper 19458079 Paper 19412867 Paper 19410956 Paper 19365016 Paper 19204236 Paper 18711463 Paper 18708627 Paper 18672221 Paper 18579112 Paper 18513266 Paper 18379933 Paper 18320151 Paper 18300089 Paper 18195232 Paper 17289891 Paper 17280866 Paper 17224956 Paper 17177965 Paper 16932659 Paper 16507484 Paper 16196117 Paper 16175040 Paper 16083834 Paper 16009838 Paper 15850812 Paper 15843513 Paper 15807864 Paper 15791161 Paper 15728534 Paper 15725575 Paper 15606475 Paper 15364234 Paper 15326137 Paper 15019332 Paper 15013890 Paper 12892739 Paper 12149073 Paper 11421029

Abstract

The goal of this project is to develop improved methods for the diagnosis and treatment of ocular inflammatory diseases (both infectious and non-infectious) in patients of all ages including uveitis, scleritis, inflammatory diseases of the ocular surface, and intraocular malignancies. This protocol allows for hypothesis generating research, clinical training of fellows yusing cutting edge diagnostic an dtherapeutic approaches for uveitis (as well as standrad of care) and masquerade syndromes. Currently, exosomes and other biomarkers as well as epigenetic modification are the focus. Additionally, the heterogeneity of primary outcome measures uses in uveitic clinical trials presents practical challenges and outcomes development reserach is also actively carried out under this protocol.

View original record on NIH RePORTER →